Accepted Articles                   Back to the articles list | Back to browse issues page

XML Print

1- Department of Pharmacology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
Purpose: Drug resistant epilepsy is an unmet medical condition that impacts 30 percent of the epileptic patients. Numerous antiseizure drugs (ASDs) have already been developed but they provide only symptomatic relief and do not target the underlying pathogenesis. Preclinical models give us the opportunities to gain insights into obscure mechanisms of Drug resistant epilepsy. Current animal models possess lacunae that need rectification and validation to discover novel antiepileptic drugs (AEDs). The present study was undertaken to validate 3 different doses of Phenobarbital (PB) at 2 different time periods.
Methods: Pentylenetetrazole (PTZ) was given at sub-convulsive dose (30 mg/kg/day/i.p.) for 28 days to develop kindling in male Wistar rats. Further, kindled rats were divided into 4 groups Pentylenetetrazole control, Pentylenetetrazole and Phenobarbital (20), Pentylenetetrazole and Phenobarbital (40), Pentylenetetrazole and Phenobarbital (60) and assessed at day 14 and 28 post kindling. Seizure scoring, oxidative stress, Phenobarbital plasma levels and histopathology of hippocampal neuron were analyzed.
Results: The results showed the combination of Pentylenetetrazole and Phenobarbital (40 and 60 mg/kg) remarkably decreased seizure score, elucidated higher antioxidant effect and prevent neuronal injury on day 14, whereas increased seizure score, oxidative stress and neuronal death was observed with chronic administration of Pentylenetetrazole and Phenobarbital in kindled rats at day 28. Moreover, Phenobarbital levels in blood were significantly increased at the end of day 28 of PB treatment as compared to day 14.
Conclusion: The adapted protocol with Phenobarbital 40 mg/kg dose could be of great potential in screening of antiseizure drugs in refractory epilepsy.
Type of Study: Original | Subject: Behavioral Neuroscience
Received: 2021/12/20 | Accepted: 2022/03/9

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Basic and Clinical Neuroscience

Designed & Developed by : Yektaweb